Preparing For Higher R&D Costs, Cardiome Raises $51M For Trials March 21, 2005 By Jennifer Boggs Expecting an increase in research and development costs this year, Cardiome Pharma Corp. is raising $51 million in a public offering to continue its clinical programs for atrial fibrillation and congestive heart failure. (BioWorld Today)Read More
